Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock
07 oct. 2021 16h01 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 oct. 2021 16h11 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...
Cidara Therapeutics to Present New Data for Rezafungin at TIMM Congress
29 sept. 2021 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021
27 sept. 2021 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
07 sept. 2021 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting compounds designed to transform the standard of care for...
Cidara Therapeutics to Host Research and Development Day
02 sept. 2021 08h00 HE
|
Cidara Therapeutics, Inc.
Virtual event will highlight the broad potential of the Cloudbreak® platform and the commercial potential for rezafungin Clinical thought leaders will highlight the risks of invasive fungal...
Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary
01 sept. 2021 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...
Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
17 août 2021 08h00 HE
|
Cidara Therapeutics, Inc.
Top-line data anticipated in late 2021 Single Phase 3 trial serves as basis for global regulatory filings SAN DIEGO and CAMBRIDGE, England, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cidara...
Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
12 août 2021 16h43 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...
Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
05 août 2021 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...